Raily Aesthetic Medicine International Holdings (HKG:2135) expects a loss attributable to owners of 59 million yuan for 2024, compared with 32 million yuan in the prior year, according to a Monday filing with the Hong Kong bourse.

The company attributed the projected wider loss to impairments provisions in the business, increased share option expenses, and higher investment in research and development.

The company is expected to publish final results by the end of March.

The aesthetic medical services company stocks were down by 2%.